Rx (Prescription Medicine)
USD $ 1,300.00
海姆利布拉 60毫克注射液用于预防血友病A患者的出血发作。本品应按照医生的处方进行皮下注射。
海姆利布拉 60毫克注射液是一种突破性药物，专为治疗血友病A（一种罕见的遗传性出血性疾病）而设计。其活性成分艾美赛珠单抗（emicizumab）是一种双特异性单克隆抗体，可模拟血液中缺失的凝血因子（凝血因子VIII）的功能。通过连接活化的凝血因子IX和凝血因子X，艾美赛珠单抗促进凝血酶原转化为凝血酶，从而促进血凝块形成并减少出血发作的频率。海姆利布拉通过皮下注射给药，通常用于血友病A患者（无论是否伴有凝血因子VIII抑制物）的常规预防（预防性治疗）。务必严格按照您的医疗保健提供者的处方使用海姆利布拉。未经医生咨询，请勿自行给药或更改剂量。将注射液储存在室温（20°C至25°C或68°F至77°F）下，并避光保存。请勿冷藏或冷冻。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Emicizumab. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
